linjc16/ctgov huggingface dataset:
Clinical and Genetic Factors on the Postoperative Recovery Time of General Anaesthesia

Study Overview
=================
Brief Summary
-----------------
To evaluate the effect of clinical factors on the recovery time of postoperative anesthesia and the effect of genetic variation in gDNA on the recovery time of postoperative anesthesia.

Detailed Description
-----------------
Recovery time of postoperative anesthesia is an important index to reflect patient's postoperative health status. The investigators want to collect patients' clinical dates and their blood samples, then extract DNA from blood samples, acquire every patients' genetic variation information. Finally, acquiring the mathematical model of the influence of clinical factors and genetic factors on the recovery time after operation, predicting the recovery time of anesthesia.

Official Title
-----------------
Clinical and Genetic Factors on the Postoperative Recovery Time of General Anaesthesia

Conditions
-----------------
General Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged more than 18 years; General anesthesia for all patients; Patients underwent surgery for laparoscopic surgery, orthopedics surgery or open surgery; Patients were not delivered allogeneic blood in three months; Having the ability to understand and sign the informed consent. Exclusion Criteria: Pregnant or lactating women; Having an immune deficiency, as a patient with HIV infection; Patients with infectious diseases, such as syphilis; Patients delivered allogeneic blood in three months; Researchers believe that may increasing the risk of subjects or interfering clinical trial; Don't have the ability to understand or sign the informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients after general anesthesia<br>Laparoscopic surgery, orthopedics surgery or open surgery patients after general anesthesia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recover time of anesthesia |  | within 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Recover time
Ischemic Preconditioning in Endurance Athletes

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the effect of remote ischemic preconditioning on biochemical and functional indices of cardiac function induced by a 30 km run in healthy trained long distance runners.

Official Title
-----------------
Influence of Remote Ischemic Preconditioning on Cardiac Function After Endurance Exercise

Conditions
-----------------
Exercise

Intervention / Treatment
-----------------
* Other: Remote ischemic preconditioning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent Healthy Age between 18 and 65 years Endurance-trained (two or more training sessions per week) Exclusion Criteria: Not applicable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Sham RIC<br>Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated. | |
| Active Comparator: Remote ischemic conditioning<br>Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times. | Other: Remote ischemic preconditioning<br>* Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum concentrations of cardiac troponins |  | 6 hours, 2 hourly time intervals | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Indices of cardiac function measured by echocardiography |  | 2 hours post-exercise |
Exercise Enhances Brain Function in Attention-deficit/Hyperactivity Disorder (ADHD)

Study Overview
=================
Brief Summary
-----------------
The aim of the study was to investigate the different effects of exercise types on inhibitory control in children with attention-deficit/ hyperactivity disorder.

Detailed Description
-----------------
Study inclusion criteria were as follows: (1) age between 8 and 12 years; (2) diagnosed with ADHD by a pediatric psychiatrist; and (3) no history of brain injury or neurological conditions, such as exhibited epileptic seizures, serious head injuries, and periods of unconsciousness.

Official Title
-----------------
Different Exercise Types on Inhibitory Control in Children With ADHD

Conditions
-----------------
Exercise, ADHD, Executive Dysfunction

Intervention / Treatment
-----------------
* Other: Exercise type


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged between 7 and 12 years diagnosed by a pediatric psychiatrist no history of brain injury no neurological conditions Exclusion Criteria: less than 50% accuracy failed to complete the task cannot follow the instruction

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Control condition<br>30 min to watching exercise-related video | Other: Exercise type<br>* Aerobic exercise and Resistance exercise<br>|
| Other: Aerobic exercise condition<br>20 minutes of moderate-intensity exercise on treadmill | Other: Exercise type<br>* Aerobic exercise and Resistance exercise<br>|
| Other: Resistance exercise condition<br>One set of 15 repetition 9 muscle exercises dumbbell squat with chair, dumbbell right/left foot lunge, sit-up, push-up, back muscle with superman, dumbbell right/left bicep curl, dumbbell calf raise. | Other: Exercise type<br>* Aerobic exercise and Resistance exercise<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Behavioral performance | reaction time of stroop and simon task following congruent and incongruent condition. | around 10-30 minutes after exercise intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| P3 component | P3 of event-related potentials component, a larger P3 amplitude and shorter P3 latency means better performance | around 10-30 minutes after exercise intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intensity, exercise, executive function, ADHD
MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis

Study Overview
=================
Brief Summary
-----------------
Estimate of clinical and microbiological efficacy of Levofloxacin (Tavanic) in combine therapy of MDR TB. Estimate of safety of Levofloxacin (Tavanic) in combine therapy of MDR TB.

Official Title
-----------------
Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB)

Conditions
-----------------
Tuberculosis, Pulmonary

Intervention / Treatment
-----------------
* Drug: Levofloxacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Drug-resistant pulmonary tuberculosis laboratory diagnosed Exclusion Criteria: Known hypersensitivity to levofloxacin, other quinolones Patient with epilepsy and central nervous system diseases Renal insufficiency with serum creatinine lower than 50 ml/min Arterial hypertension, ischemic heart disease in acute phase Gastro-intestinal diseases, liver diseases in acute phase History of drug and alcohol abuse Patient with history of tendon disorders related to fluoroquinolone administration Pregnancy and breast-feeding women Immune system disorders related to chemotherapy, AIDS, long term administration of corticosteroids The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Levofloxacin | Drug: Levofloxacin<br>* 500-1000 mg once a day daily per os with combination of drugs.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with bacterioexcretion |  | 1 month, 2 months, 3 months | 
| Dynamics of chest radiograph |  | 3 months | 
| Dynamics of Intoxication |  | 1 month, 2 months, 3 months | 
| All clinical and laboratory adverse events |  | from the signature of the Informed Concent Form (ICF) up to the end of the study |
A COVID-19 Symptom, Exposure and Immune Response Registry

Study Overview
=================
Brief Summary
-----------------
This is a 6-month, 100% remote study that will collect a broad range of data that may provide insight into the COVID-19 global pandemic. Data collected will include participant medical histories, history of prior SARS-CoV-2 infection and exposure to known cases. On an ongoing basis data will be collected on new contacts with known cases, the presence of COVID-19 symptoms, including severity and outcome, and information on the immune system response to SARS-CoV-2 infection.

Detailed Description
-----------------
This is a 6-month, 100% remote study that will collect a broad range of data that may provide insight into the COVID-19 global pandemic. All data will be collected by participant entry into a mobile app designed for this study. Upon entering the study, participants will be asked a series of questions about their prior exposure to the SARS-CoV-2 virus including reporting prior test results, and identification and description of contact with known or cases or other high risk encounters. Participants will also provide a detailed medical history. On on ongoing basis, participants will be asked to report any symptoms associated with COVID-19 that they develop, and any new contacts they experience with known cases. Some participants will be sent an at-home SARS-CoV-2 antibody test and asked to report the results. In addition, participants will be asked to report the result of any other test they receive for COVID-19 outside of the study.

Official Title
-----------------
COVID-19 Study - A Primarily Prospective Observational Study of COVID-19 Clinical Characteristics and Acquired Immune Response Within the General Population

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Open to any adult individuals (18 years of age or older) permanently residing in the United States Have regular access to smartphone and internet sufficient to support registry demands Willing and able to follow the procedures of the study Willing and able to provide informed consent Exclusion Criteria: Participants unable to understand the study protocol or provide informed consent Participants unable or unwilling to perform all requested study tasks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Registry Data | Compilation of registry data via regular self-reported questionnaires on symptoms (known to be associated with COVID-19 diagnosis including presence, severity, and duration using the Obvio-19 app. | 6 months |
Soreness After Deep Dry Needling of One Latent Myofascial Trigger Point

Study Overview
=================
Brief Summary
-----------------
Pain after dry needling or injection in the muscle is a frequent secondary effect in the treatment of myofascial pain syndrome. In this trial pain and sensitivity will be assessed during a 72 hours follow up period. Factors that may contribute to higher levels of pain or sensitivity will be evaluated.

Conditions
-----------------
Pain After Dry Needling

Intervention / Treatment
-----------------
* Procedure: Deep dry needling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The latent MTrP diagnosis was based upon the following criteria:10 presence of a palpable taut band in the muscle presence of a hypersensitive tender spot in the taut band palpable or visible local twitch response with snapping palpation of the tout band referred pain elicitation in response to compression. Exclusion Criteria: presence of coagulation disorders neck or facial pain previous application of a dry needling technique MTrP therapy in head or neck within the previous 3 months fibromyalgia an insurmountable fear of needles as a reason of refusing the treatment history of surgery in the head or neck area.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Latent trigger point in the upper trapezius muscle<br> | Procedure: Deep dry needling<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | Visual analogue scale | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity | Pressure pain threshold | 72 hours |
Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
Laryngeal squamous cell carcinoma (LSCC) is the second most common primary malignant tumor of the respiratory tract after lung cancer and the second most common primary epithelial malignant tumor of the head and neck. The age of onset of LSCC is mostly between 50 and 70 years, with a male to female ratio of approximately 4:1 .According to estimates by the American Cancer Society, in the United States, approximately 12,470 new cases of laryngeal cancer will be diagnosed and 3,820 people will die from laryngeal cancer in 2022. The nuclear vitamin D receptor (VDR) is involved in multiple pathways that have many points of convergence. Some of these pathways are implicated in carcinogenesis thus the suggestion that VDR has a role to play in the biology of cancer [3]. Recent evidence indicates that the active form of vitamin D (1alpha, 25-dihydroxycholecalciferol) (VD) exhibits several different effects on normal and cancerous cells, including up-regulation of anti- proliferation and pro-apoptotic factors, as well as inhibition of cell-cycle promoters and growth factor signaling pathways. Thus it is useful as an anti-neoplastic agent in several human malignancies. Studies in cell and animal model systems, as well as clinical trials have recognized the potential usefulness of VD and VD analogues as agents that enhance the anti-proliferative/cytotoxic effects of chemotherapy and ionizing radiation. Thus, at concentrations that produce limited hypercalcemia, these agents may be used as adjuncts to conventional chemotherapy and radiotherapy. We aim to analyze the expression of VDR in LSCC to determine potential for active VD therapy in such patients.

Official Title
-----------------
Immunohistochemical Expression of Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma

Conditions
-----------------
Laryngeal Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both endoscopic and excisional biopsy specimens. All the studied cases include sufficient materials for the immunohistochemical study. Complete clinical data Exclusion Criteria: Patients with recurrence of the primary tumor. Patients with a history of preoperative chemotherapy and/or radiotherapy. Insufficient or tiny tissue biopsies

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis and prognosis of laryngeal squamous cell carcinoma | Immunohistochemical Expression of Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma | Two or three days after staining tissue sections with Vit D receptor antibody |
Long Term Clinical Implications in Chinese Patients With Aortic Intramural Hematoma

Study Overview
=================
Brief Summary
-----------------
The study evaluates outcomes of intramural hematomas after long-term follow up and establish predictive factors in Chinese population.

Detailed Description
-----------------
270 intramural hematoma patients with clinical and imaging follow up were retrospectively studied in present study. The primary endpoint was consisted of aortic disease-related death, aortic dissection, penetrating atherosclerotic aortic ulcer , thickening of aorta hematoma and aortic complications requiring surgical or endovascular treatment.

Official Title
-----------------
Long Term Follow-up and Clinical Implications in Chinese Patients With Aortic Intramural Hematoma

Conditions
-----------------
Aortic Intramural Hematoma

Intervention / Treatment
-----------------
* Other: drug, stent, surgical treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type A aortic hematoma Type B aortic hematoma Exclusion Criteria: Aortic without initial intimal flap formation.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 87 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: drug, stent, surgical treatment|drug, stent, surgical treatment|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hematoma thickness and a baseline MAD | Medication and short-term imaging are recommended for Chinese IMH patients with a hematoma thickness less than 10.45 mm and a baseline MAD less than 44.75 mm. Rigorous medical observation should also be performed during the acute phase of IMH. | 14years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aortic intramural hematoma, Chinese patients, Clinical outcomes
Effects of Glutamine on GLP-1 and Insulin Secretion in Man

Study Overview
=================
Brief Summary
-----------------
This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.

Detailed Description
-----------------
In this study, we investigated the effect of glutamine, an amino acid, on glycemia and on GLP-1 and insulin in participants with type 2 diabetes. Preliminary data published by our group suggests that glutamine is a strong determinant of GLP-1 secretion in vitro. We tested the hypothesis that glutamine lowers postprandial blood glucose and investigated whether the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin modifies this effect.

Official Title
-----------------
Study of the Effects of Glutamine on Glycemia, Glucagon-like Peptide-1 (GLP-1) and Insulin Secretion in Man

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Drug: Sitagliptin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes, on metformin or diet alone (not sulphonylureas or insulin) Exclusion Criteria: Malabsorption, renal or liver disease, treatment with steroids

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Glutamine+Sitagliptin<br>Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin | Drug: Sitagliptin<br>* Glutamine 30g +sitagliptin 100mg<br>* Other names: Januvia;|
| Placebo Comparator: Glutamine+Placebo<br>Glutamine 30 g/d (15 g with breakfast and dinner) + placebo | Drug: Placebo<br>* Glutamine 30g +placebo (matching sitagliptin 100 mg)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postprandial Glucose Area Under the Curve (AUC) | The area under the curve (AUC) of the postprandial glucose following a meal challenge | 0 to 180 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fructosamine | The blood concentration of the glycemic control marker fructosamine | 4 weeks |